COMMUNIQUÉS West-GlobeNewswire

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

27/02/2025 - 22:05

DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]

Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results

27/02/2025 - 22:05

Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase [...]

Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

27/02/2025 - 22:05

Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well [...]

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

27/02/2025 - 22:05

CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results

27/02/2025 - 22:05

PONTE VEDRA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

27/02/2025 - 22:05

Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming months Enrollment completed in Qilu’s Phase 2 trial evaluating certepetide for the [...]

ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance

27/02/2025 - 22:05

SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

27/02/2025 - 22:05

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE [...]

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

27/02/2025 - 22:05

- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40 million underwritten registered [...]

TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

27/02/2025 - 22:05

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

27/02/2025 - 22:05

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]

LeMaitre Q4 2024 Financial Results

27/02/2025 - 22:05

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+ [...]

Pennant Reports Fourth Quarter and Fiscal Year 2024 Results

27/02/2025 - 22:08

Conference Call and Webcast scheduled for tomorrow, February 28, 2025 at 10:00 am MT EAGLE, Idaho, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]

GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2024

27/02/2025 - 22:10

Trésorerie et équivalents de trésorerie : 81,8 millions d’euros au 31 décembre 2024 Chiffre d’affaires : 67,0 millions d’euros au 31 décembre 2024, dont 48,7 millions d'euros de paiement d'étape lors de la première [...]

GENFIT Announces Revenues and Cash Position as of December 31, 2024

27/02/2025 - 22:10

Cash and cash equivalents totaled €81.8 million as of December 31, 2024 Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen’s Iqirvo® (elafibranor) [...]

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

27/02/2025 - 22:10

Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended [...]

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

27/02/2025 - 22:10

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 - [...]

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

27/02/2025 - 22:15

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to [...]

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

27/02/2025 - 22:15

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data [...]